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ABSTRACT 
Mathematical models are often used in describing immune response to HIV 
infection, and treatment against HIV infection can be improved through the study of 
these descriptions. One such model from Kirschner and Webb's paper, "Immunotherapy 
ofHIV -1 Infection," uses a system of two differential equations to model the interaction 
of the AIDS virus and CD4+ T -cells. Beginning with this existing model, we modify the 
equations to include the mathematical representation of a theoretical antiviral treatment 
based on maximizing the benefit to the patient. Solving this problem requires both 
analytic and numerical evaluations, and a numerical example is provided to illustrate the 
form of a treatment schedule. In solving the optimal control problem we learn how to 
best administer such a treatment to extend the life of the patient. 
I. Introduction: 
Mathematical models provide great insight into the workings of many biological 
environments. Quantifying the living world helps in the understanding of the dynamics within 
organisms and assists in medical studies, environmental studies, and other areas of biological 
benefit In medicine specifically, mathematical models can represent the actions of disease, and 
medical researchers can find optimal ways of treating infection through the use of such models. 
By the understanding of the dynamics of the immune system and its responses, the study of 
medicine can advance in efficiency of treatments. 
Many different researchers have considered the immune system's mathematical basis, 
recognizing the potential for describing immune cell numbers in terms of simple population 
models. When infectious cells, viruses, bacteria, etc., enter the body, the relationship between 
immune cells and invading cells becomes much like a predator-prey relationship. When the body 
becomes infected with the Human Immunodeficiency Virus, however, the system immediately 
becomes more complicated. Many researchers and mathematicians have dealt with the topic of 
mv infection described through mathematical modeling, and hopefully their work will help in the 
treatment of the terminal disease. The different models have their own advantages and 
disadvantages so one model will not necessarily lead to the "cure" for mv infection. Through 
the study of these models, researchers can continually make improvements to the existing systems 
and hopefully achieve the best treatment possible. 
Control theory is the mathematical study of adjusting features of systems to achieve 
desired goals. When relating control theory to medical models such as those involving HIV 
infection, we must consider the patient's threshold for treatment while we strive for the highest 
3 
achievable results of patient benefit (Fleming 2). Using an existing model from "Immunotherapy 
ofHIV-Infection" (Kirschner 73-74), we mathematically controlled the system in order to find the 
best way to administer a certain type of treatment for the infection. The theoretical treatnlent 
used in this evaluation fights HIV by inhibiting the proliferation of virus particles by infected T-
cells. By using control theory, we hoped to find an analytica1lnumerical representation of 
treatment that maximizes benefit to the patient. 
II. Existing HIV Modeling 
Mathematical models of HIV infection vary in many respects, but all basically begin with 
the underlying idea somewhat similar to a predator-prey or competition relationship. Because 
HIV infects immune cells themselves, the relationship between T -cells and HIV becomes very 
complicated. HIV models have many factors to consider, and some models involve several 
equations. One system from "Mathematical Analysis of Antiretroviral Therapy Aimed at HIV-1 
Eradication or Maintenance of Low Viral Loads" models HIV infection with a ten differential 
equation model (Wein 83). Models ofHIV infection range from highly complex to fairly simple, 
varying in assumptions and in the populations considered. 
The majority of mathematical models of viruses concern HIV -1, for HIV -1 is the most 
studied human virus (Regoes 451). As stated in "Virus Dynamics: the Effect of Target Cell 
Limitation and Immune Responses on Virus Evolution," seven assumptions underlie the theory of 
HIV -1 progression. These assumptions are 
(I) virus load causes disease; (ii) immune responses reduce virus load; (iii) HIV-1 
can impair immune responses by killing CD4 cells; (iv) there is continuous and 
rapid virus replication throughout the course of infection; ( v) the rapid turnover 
leads to a large number of virus mutants; (vi) some of these mutants can escape 
from immune responses; (vii) the virus may evolve towards faster replication rates 
during infection (451-452). 
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Although not all models incorporate mutations, these assumptions relate the basic idea of the 
situation being modeled. 
One specific model of the dynamics of mv infection is "Immunotherapy of mV-1 
Infection" by D.E. Kirschner and G.F. Webb. This paper assesses the benefit of using 
interleukins, a specific type of cytokine, to boost the immune response to the infection (Kirschner 
71). Kirschner and Webb model the immune response to mv -1 infection using only the 
populations of virus particles and of T -cells. They do not use different states of the T -cells (e. g., 
infected and latent, infected and actively producing virus), and hence their model is relatively 
simple in comparison to many other existing models. Kirschner and Webb's work resulted in the 
two equation system of ordinary differential equations, 
dT = sl - (s2)V - JlT - kVT 
dt (b1 + V) 
dV - cVT 
dt (b2 + V) 
in which T represents the concentration of CD4+ T -cells as a function of time and V represents 
the concentration of free virus particles as a function of time. The first two terms of dT/dt 
represent the source and proliferation of healthy CD4+ T -cells and s 1 =20 and s2= 1. 5. The values 
b1 and b2 are half saturation constants and they equal 14.0 and 1.0, respectively. The value -JlT 
is a natural death term and -k VT involves the loss of T -cells to viral infection. The value Jl, death 
rate ofuninfected T-cells, is 0.002; and k, the rate of infection by free virus, is 2.5*10A-4. The 
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term gV/(b2 + V) involves virus proliferation from several areas other than plasma such as the 
lymph system. The value g, input rate of external viral source, is 30. The initial value for T for 
the model is 1000.0, but three different values in different versions of the paper are listed for 
initial V: 1.0, 1000, 3000. The model is fundamentally a modified predator-prey or (more 
accurately) competition relationship with interaction terms of -kVT and -cVT. (In their paper, 
Kirschner and Webb further modified the system with a drug input function r( t) representing the 
interleukin treatment by adding the term r(t)T to the dT/dt equation.) 
III. Implementation of the Antiviral Function 
The original system devised by Kirschner and Webb was re-evaluated in its original form 
and modified to include an antiviral treatment inhibiting the production of virus particles. Using 
control theory, the optimal treatment schedule can be calculated for this treatment. Because the 
treatment affects virus proliferation, the effect of the control function u( t) is the coefficient of the 
proliferation term for the virus population. For controls u(t) such that .1 < u(t) < .9, our state 
system is 
dT 2.0 - - .002T - (2.5*101\(-4))VT 
dt (14.0 + V) 
dV = 30V( .9-u(t) ) - .007VT . 
dt (1.0 + V) 
IV. Evaluation of the System 
When creating the best situation for the patient, we must consider both the positive and 
negative results of the treatment. In order to maximize the benefit to the patient, we must 
maximize the objective functional, 
t1 
J ( T(t) - (l;2)PU2(t) ) dt 
o 
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which represents the benefit to the immune system through increased concentration of T -cells 
minus the systemic cost of the treatment. By finding u*(t), the optimal treatment which 
maximizes this integral, we find the treatment schedule which provides the greatest overall benefit 
to the patient. When maximizing this integral, we must first find and utilize the Hamiltonian of the 
system, 
H ( T -(l;2)pu2(t) ) + AI(dT/dt) + A2(dV/dt), 
where Al and A2 are functions dependent on values ofT, V, and time (Kamien 124-128). Solving 
the optimality equation, aH/au = 0, gives the optimal equation for the treatment, 
{ 0.1 u < 0.1 
-A2*30V 
u*(t) = { -------------- 0.1 <u<0.9 
P*(1.0+V) 
{ 0.9 u>0.9 
The adjoint equations, A1'=(-BHlBT) and A2'=(-BHlBV), evaluated from the Hamiltonian are 
Al '=AI *(.002+.007V) + A2*(2.5*10A(-4)V - 1.0 
A2'=A1 *( 21.0 + (2.5*10A(-4»T ) - A2*( 27.0-30u -.007T) 
(14.0+v)2 (1.0+V)2 
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which are necessary in finding the numerical solution of the modified system. To determine if 
these equations do in fact produce a maximum value for the functional, we must verify that the 
second partial derivative of the Hamiltonian with respect to u*(t) is negative. We find that 
8ZHlauz -~; therefore, choosing ~>O will make u*(t) the optimal treatment function. 
Solving the model itself must be done numerically. The original model was re-solved 
using the classic Fourth Order Runge-Kutta method written in a Fortran code (Appendix A). The 
values of the T -cells decrease and the values of the virus increase so quickly initially that an 
extremely small step-size must be used or the values will become negative. The initial 
concentration ofT-cells, TO, was set at 500.0 in the newly modified system rather than 
TO=1000.0 as in the original paper. The initial value was lowered in order to simulate a later 
stage of infection. The original model lists three initial values for the virus population in two 
different copies of the paper (one copy prior to publication), but the value 1000.0 was used in this 
evaluation because this value was included in the actual published result and the re-evaluation 
results seemed logical. The value ~= 124.0 was chosen because it provided the best results and 
did not violate the condition 13>0. The optimality system, which is the original T(t) and V(t) 
ODEs coupled with adjoint ODEs including the control u*(t), was evaluated using an iterative 
method with the Classic Fourth Order Runge-Kutta Method in a FORTRAN code (Appendix B). 
Numerical solutions were found for the resulting functions of the T-cell population with respect to 
time, the virus population with respect to time, as well as the treatment schedule over time. The 
nunlerical results for the original system and the optimized system were computed in the 
respective FORTRAN codes then graphed using MA TLAB. 
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V. Results and Discussion 
The virus population values decrease in the presence of treatment (Figure 1 and Figure 2) 
although the results do not appear to be drastic. The numerical results to the original system 
show a steady decline in the T-cell population (Figure 3), but the population of the T -cells 
behaves quite differently in the presence of treatment. The positive change in T-cell numbers in 
the presence of treatment is quite obvious (Figure 4), with T-cell numbers increasing over the 
majority of the treatment period and gradually declining near the end of the treatment period. 
Hence, the treatment schedule does appear to increase the T-cell population over the course of 
treatment and therefore seems to benefit the patient. The numerical results for u*(t), the 
treatment schedule (Figure 5). includes high levels of treatment at the beginning of the treatment 
period with the dosage decreasing over the course of treatment. This result suggests that an 
intense treatment is very beneficial initially in the treatment schedule, but maintaining that strength 
of treatment would not result in the overall best situation for the patient. Most likely the negative 
effects of the drug outweigh the benefits of high treatment levels as time progresses. 
Although the treatment discussed here is theoretical, current treatments exist inhibiting 
different stages ofillV infection which affect the progression of the disease in various major 
ways, including the prevention of binding ofHIV to the surface of the host cell and the inhibition 
of reverse transcription of RNA from the HIV particle into T-cell DNA. The treatment evaluated 
in this paper is assumed to treat through inhibition of one or more stages of viral production. The 
combined use of different treatments, i.e., a "drug cocktail," has the potential for highly favorable 
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Figure 1 
Virus population vs. time in the presence of treatment 











0 200 400 600 800 1000 1200 
Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
Appendix A 
c This program solves a of differential equations modeling 
.c the action of the immune system in response to HIV infection. The 
c model comes from "Immunotherapy of HIV-l Infection," D.E. Kirschner 
c and G.F. Webb, Journal of Biological Systems. 
implicit none 
real ti, tf, h, t, v 
integer n, i 
real xn(2,1001), xl, x2, kx(2,4) 
c The original differential equations are entered: 
xl (t,v) 
x2(t,v) 
2.0 - (1.5*v)/(14.0+v) - .002*t - (2.5e-4)*v*t 
30.0*v/{1.0+v) .007*v*t 
c Initialize values: 
n = 1000 
ti = 0.0 
tf = 100.0 
h = (tf-ti)/n 


























c This program solves a system of differential equations modeling 
c the action of the immune system in response to HIV infection. The 
c model comes from "Immunotherapy of HIV-1 Infection," D.E. Kirschner 
c and G.F. Webb, Journal of Biological Systems. The original system 








c The original differential equations are entered: 
x1{t,v) = 2.0 - (1.5*v)/{14.0+v) - .002*t (2.5e-4)*v*t 
x2{t,v,c) 30.0*v*{.9-c)/{1.0+v) .007*v*t 
y1{adj1,adj2,v) = adj1*{.002+.007*v)+adj2*{2.5e-4)*v-1.0 
y2{adj1,adj2,t,v,c) = adj1*({21.0/«14.0+v)*{14.0+v»)+ 
! (2.5e-4)*t)-adj2*«27.0-30.0*c)/«1.0+v)*(1.0+v»-.007*t) 
c Initialize values: 
n = 1000 
ti 0.0 
tf = 100.0 
h = (tf-ti)/n 
beta 124.0 
tol 10.0 
c Initial values are set for the loops: 
xn(l,l) = 500.0 











yold (1, m) 1. 0 
yold(2,m) 1.0 
ENDDO 




c Here, need to add small loop for u bdd by M: 
u(i)=«-1.0)*yn(2,i)*30.0*xn(2,i»/(beta*{1.0+xn(2,i») 
if (u (i) . It. .1) then 
u(i} .1 
elseif(u(i) .gt .. 9) then 
u(i)=.9 
endif 
















c Begin loop for R-K for adjoints: 
DO ii=l,n 
c Here, need to add small loop for u bdd by M: 
u(ii)=«-1.0)*yn(2,ii)*30.0*xn(2,ii»/(beta*(1.0+xn(2, ii») 
if (u (ii) .It. .1) then 
u(ii)=.l 




































epsxl + abs(xn(l,p)-xold(l,p» 
epsx2 + abs(xn(2,p)-xold(2,p» 
epsyl + abs(yn(l,p)-yold(l,p» 
epsy2 + abs(yn(2,p)-yold(2,p» 
eps = epsxl + epsx2 + epsyl + epsy2 




print*, 'T-cell: Virus: Adjl: Adj2: 
DO k=l,n+l,20 
u: ' 




print*, 'final values:' 
print*, 'T-cell:' ,xn(l,n+l) ,'Virus:',xn(2,n+l) 
print*, 'Adjl:',yn(l,n+l), 'Adj2:',yn(2,n+l) 
goto 45 
elseif (counter .gt. 20) then 
print*, 'convergence not reached' 
print*, 'last values are:' 
DO s=l,n+l,50 
print*,xn(l,k),' , ,xn(2,k),' , ,yn(l,k),' ',yn{2,k),' , ,u{k) 
ENDDO 
print*, 'exiting .... ' 
goto 45 
else 
DO q=l,n+l 
xold(l,q)=xn{l,q) 
xold(2,q)=xn(2,q) 
yold(l,q)=yn(l,q) 
yold{2,q)=yn{2,q) 
ENDDO 
goto 25 
endif 
stop 
end 
